structure of (E)-2-[[3-(3-methoxy-4-propargyloxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid

(E)-2-[[3-(3-methoxy-4-propargyloxyphenyl)-1-oxo-2-propenyl]amino]benzoic acid

CAS No.: 1001288-58-9
M. Wt: 351.353
M. Fa: C20H17NO5
InChI Key: UIWZIDIJCUEOMT-PKNBQFBNSA-N
Appearance: Pale-yellow Solid

Names and Identifiers of 1001288-58-9

CAS Number

1001288-58-9

IUPAC Name

2-[[(E)-3-(3-methoxy-4-prop-2-ynoxyphenyl)prop-2-enoyl]amino]benzoic acid

InChI

InChI=1S/C20H17NO5/c1-3-12-26-17-10-8-14(13-18(17)25-2)9-11-19(22)21-16-7-5-4-6-15(16)20(23)24/h1,4-11,13H,12H2,2H3,(H,21,22)(H,23,24)/b11-9+

InChIKey

UIWZIDIJCUEOMT-PKNBQFBNSA-N

Canonical SMILES

COC1=C(C=CC(=C1)C=CC(=O)NC2=CC=CC=C2C(=O)O)OCC#C

Isomeric SMILES

COC1=C(C=CC(=C1)/C=C/C(=O)NC2=CC=CC=C2C(=O)O)OCC#C

UNII

C6V7ZU2NPR

Physical and chemical properties of 1001288-58-9

Acidity coefficient

3.45±0.36(Predicted)

Boiling Point

618.9±55.0 °C at 760 mmHg

Density

1.3±0.1 g/cm3

Exact Mass

351.110687

Flash Point

328.1±31.5 °C

Index of Refraction

1.656

LogP

4.39

Molecular Formula

C20H17NO5

Molecular Weight

351.353

Storage condition

2-8℃

Vapour Pressure

0.0±1.9 mmHg at 25°C

Applications of 1001288-58-9

Unique FeaturesTranilastInhibition of cytokine-induced collagen synthesisAllergic diseases, fibrosisFirst identified as an anti-allergic agent; broader usesPirfenidoneInhibition of fibroblast proliferationIdiopathic pulmonary fibrosisAlso has anti-inflammatory effects; FDA-approvedNintedanibTyrosine kinase inhibitor targeting multiple pathwaysIdiopathic pulmonary fibrosisMulti-targeted approach; inhibits angiogenesisGalunisertibInhibition of transforming growth factor-beta signalingCancer treatmentFocused on tumor microenvironment modulation

Interaction Studies of 1001288-58-9

Interaction studies involving FT011 have focused on its effects on various signaling pathways related to fibrosis and inflammation:

  • Transforming Growth Factor-Beta Pathway: FT011 modulates this pathway, which is critical in fibrogenesis.
  • Platelet-Derived Growth Factor Signaling: The compound inhibits the proliferative effects of this growth factor on mesangial cells.
  • Inflammatory Cytokine Modulation: FT011 reduces levels of intercellular adhesion molecules and other inflammatory markers in animal models of diabetes.

These studies highlight FT011's potential as a multi-targeted therapeutic agent.

Biological Activity of 1001288-58-9

FT011 exhibits a range of biological activities that contribute to its therapeutic potential:

  • Anti-fibrotic Effects: FT011 has been shown to significantly reduce collagen deposition in various tissues, thereby mitigating fibrosis in models of chronic kidney disease and diabetic cardiomyopathy.
  • Anti-inflammatory Properties: The compound reduces inflammation by inhibiting the expression of pro-inflammatory cytokines and chemokines, which are often elevated in fibrotic diseases.
  • Cardiorenal Protection: FT011 has demonstrated protective effects on kidney and heart function in experimental models, suggesting its utility in treating cardiorenal syndromes associated with diabetes.

Physical sample testing spectrum (NMR) of 1001288-58-9

Physical sample testing spectrum (NMR) of 1001288-58-9

Retrosynthesis analysis of 1001288-58-9

  • Route#1

    Cas:118-92-3
    Cas:1001288-58-9

  • Route#2

    Cas:121-33-5
    Cas:1001288-58-9